Navigation Links
Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007 /PRNewswire-FirstCall/ -- Data analyses from the largest initial registration clinical trial program ever undertaken in the renal anemia arena provide efficacy and safety information on the investigational anemia therapy MIRCERA(TM) for the treatment of renal anemia associated with chronic kidney disease (CKD) in patients on dialysis and not on dialysis. Three data analyses were presented at the National Kidney Foundation 2007 Spring Clinical Meetings in Orlando, Florida.

According to these analyses, MIRCERA with extended dosing up to once every four weeks: (1) corrected and maintained hemoglobin (Hb) levels in patients with CKD, on dialysis and not on dialysis; (2) maintained Hb levels in dialysis patients, regardless of congestive heart failure (CHF) status as shown in a post-hoc analysis; and (3) exhibited a safety profile that is consistent with that of commercially available erythropoiesis stimulating agents (ESAs) and typical of those associated with this patient population.

"The goal in treating renal anemia is to safely maintain target hemoglobin levels," said Steven Fishbane, MD, Associate Director of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease research at Winthrop University Hospital. "These data analyses clearly demonstrate that MIRCERA corrected low hemoglobin levels, and maintained target hemoglobin levels with the added convenience of up to once- monthly dosing."

About the Studies

Safety and Tolerability of C.E.R.A. In Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials

Pooled data from four Phase II and six Phase III studies evaluated the safety and tolerability of MIRCERA (intravenous (IV) and subcutaneous (SC)) in patients not previously treated with commercially available ESAs and those previously treated with commercially availa
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
5. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
6. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 11, 2011 MonoSol Rx, a specialty pharmaceutical ... platform, in collaboration with APR Applied Pharma Research ... FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is ... Company made the strategic decision to reacquire the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Systemic ... and hope to market ... order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Group, Inc. will provide substantial ... revenues for the company, ... American Health Resorts, Inc. (Pink Sheets:,CAHR) of Beverly Hills, California, today ... corporate note deal valued at,approximately $8 million., With Momentum Medical ...
... ... Total Debt Reduced, BIRMINGHAM, Ala., Feb. 25 HealthSouth,Corporation (NYSE: ... the fourth quarter ended December 31, 2007. Compared to the,fourth quarter ... by 4.6% and discharges increased by,0.9%., "We are pleased with ...
... 25 Lung Cancer Alliance,(LCA) cautioned today that recently ... more people each year than all the other,major cancers ... of government statistics,entitled Cancer Facts and Figures for 2008, ... been made against cancer over the,past 15 years.", ...
... ... - ANNUAL REVENUES INCREASED 34.5% ... FFO PER SHARE UP 7.8%, NEWPORT BEACH, Calif., Feb. 25 Nationwide,Health Properties, Inc. ... investment activity., "We ended 2007 on a strong note with fourth quarter revenues up ...
... COLUMBUS, Ohio Scientists have identified the role of ... in resisting certain classes of antibiotics. , The finding ... could target bacterial resistance at its cellular source. Before ... of the activities at play in the conflict between ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) ... on March 3, 2008. Management will not be ... and explanations of,variances will be included in the ... be released before markets open., About Sunrise ...
Cached Medicine News:Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 2Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 3Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 2Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 3Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 5Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 6Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 7Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 8Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 9Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 10Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 11Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 12Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 13Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 14Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 15Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 16Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 17Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 18Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 19Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 20Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 21Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 22Health News:'Enormous Progress' in Reducing Cancer Does Not Include Lung Cancer 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 3Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 4Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 5Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 6Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 7Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 8Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 9Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 10Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 11
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: